Tachykinin receptor blockers have the potential to treat stress-induced anxiety and aggression, but economic barriers hinder their clinical development.

“I remain convinced that this family of drugs could have very powerful uses in treating some forms of stress-induced anxiety or aggressiveness in humans, but it's just very difficult, for economic reasons, to find a way to get somebody to test that.”